AML | Clinical

Ivosidenib Plus Azacitidine Shows EFS Benefit in IDH1+ Acute Myeloid Leukemia

August 02, 2021

Treatment with ivosidenib tablets in combination with azacitidine led to improvement in event-free survival in patients with previously untreated IDH1-mutated acute myeloid leukemia, meeting the primary end point of the phase 3 AGILE study.

FDA Lifts Partial Clinical from Study of RVU120 in Relapsed/Refractory AML and MDS

July 15, 2021

The FDA has lifted its partial clinical hold on a phase 1B study of RVU120, which is an investigation of the agent for the treatment of patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome.